Article
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
All News
Article
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.
Article
A EULAR taskforce has evaluated the effect of lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs) and concluded that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposures on outcomes in RMDs is lacking.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Article
Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
Article
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. John Cush
Tweet
Memory B cells are dysfunctional in #SLE. They are anergic B cell receptor signalling, but responsiveness to Toll-like receptor (TLR) and type I interferon signalling. BCR hyporesponsiveness of memory B cells may explain failure non-depleting B cell Rx in SLE… https://t.co/naBYtgLBGd https://t.co/5sJibS9esn
Dr. John Cush
Tweet
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush
Tweet
Iberdomide Efficacy in Cutaneous Lupus
berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk
Dr. John Cush
Tweet
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush
Tweet
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/or6vuCZASs https://t.co/UxzSR6yJO5
Dr. John Cush
Tweet
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush
Tweet
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN
Dr. John Cush
Tweet
Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN)
- 60% PGN w ≤1 g/d proteinuria (more renal recovery)
- 79% w/ 1-3g/d
- 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush
Tweet
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv
Dr. John Cush
Tweet
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb
Dr. John Cush
Tweet
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Dr. John Cush
Tweet
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush
Tweet
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before… https://t.co/31dqOyD3ZR https://t.co/L9LMn2CPYS
